Table 1 Mechanisms of ferroptosis in urological cancers

Prostate cancer

HDECR1 silencing induced ferroptosis by accumulation of PUFAs and then promoting ROS generation

[38]

Silencing of PANX2 promoted ferroptosis by suppressing the expression of Nrf2

[41]

PI3K/AKT/mTOR inhibited ferroptosis via upregulating SREBP1/SCD1

[50]

HSPB1inhibited ferroptosis by promoting iron uptake and increasing lipid ROS production

[65]

Bicalutamide-iron combination induced ferroptosis

[28]

The combination of erastin and docetaxel induced ferroptosis

[111]

CHAC1 inhibits cell viability and increases the sensitivity of prostate cancer cells to docetaxel by inducing ferroptosis

[67]

Therapy-induced lipid uptake and remodeling underpin GPX4 dependence and ferroptosis hypersensitivity

[70]

Kidney cancer

VHL/HIF-2α induced ferroptosis via elevating lipid peroxidation levels through HILPDA

[73]

TAZ silencing reduce sensitivity to erastin-induced ferroptosis by downregulating the expression of EMP1-NOX4

[79]

ACOT8 inhibited ferroptosis

[86]

Repression of SUV39H1 induced ferroptosis via enhancing DPP4 activity

[89]

The low-expression of NCOA4 conferred ccRCC cells resistance to ferroptosis by increasing FTH and FTMT expression levels

[96]

GPX1 induced ferroptosis in KIPP

[101]

ART induced ferroptosis and enhanced the anti-tumor effect of sunitinib

[118, 119]

Bladder cancer

CPNPs targeted to EDNRB via EDN3-CPNPs and thereby induced ferroptosis

[121]

Quinazolinyl-arylurea derivatives induced ferroptosis through ROS generation and GSH depletion

[122]